SCHEMBL8745456

SCHEMBL8745456

CCOC(=O)[C@H](Cc1cc(I)c(Oc2ccc(OC)cc2)c(I)c1)NC(C)=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PCNA P12004 8/20 0.55
TACR1 P25103 2/20 0.43
ALDH1A1 P00352 2/20 0.43
THRB P10828 5/20 0.42
LMNA P02545 4/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
THRA P10827 3/20 0.42
PPARG P37231 2/20 0.42
CYP2D6 P10635 1/20 0.42
TSHR P16473 1/20 0.42
GABRP O00591 1/20 0.42
GABRD O14764 1/20 0.42
ABCB11 O95342 1/20 0.42
F2 P00734 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRB1 P18505 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
ADORA1 P30542 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28094930 1.00 PCNA (0.55) PCNATACR1ALDH1A1THRBLMNA
SCHEMBL28680811 0.91 PCNA (0.67) PCNATACR1THRBLMNAMEN1
SCHEMBL28680813 0.91 PCNA (0.67) PCNATACR1THRBLMNAMEN1
SCHEMBL7631233 0.87 TACR1 (0.43) PCNATACR1ALDH1A1MEN1KMT2A
SCHEMBL6723723 0.86 THRB (0.58) PCNATACR1ALDH1A1THRBLMNA
SCHEMBL6723726 0.86 THRB (0.58) PCNATACR1ALDH1A1THRBLMNA
SCHEMBL30592753 0.85 ACACB (0.51) TACR1ALDH1A1KMT2A
SCHEMBL8745407 0.84 PCNA (0.59) PCNAALDH1A1THRBLMNAMEN1
SCHEMBL14370512 0.83 ACACB (0.54) TACR1ALDH1A1KMT2A
SCHEMBL11674845 0.83 ACACB (0.54) TACR1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116715597-B Production process of levothyroxine sodium 湖北潜龙药业有限公司 2025-03-07 CN claimed
CN-116715597-A Production process of levothyroxine sodium 湖北潜龙药业有限公司 2023-09-08 CN claimed
CN-109761830-B Preparation method of levothyroxine sodium 珐玛赫(天津)科技有限公司 2021-12-17 CN claimed
CN-116715597-B Production process of levothyroxine sodium 湖北潜龙药业有限公司 2025-03-07 CN disclosed
CN-116715597-B Production process of levothyroxine sodium 湖北潜龙药业有限公司 2025-03-07 CN disclosed
CN-116715597-A Production process of levothyroxine sodium 湖北潜龙药业有限公司 2023-09-08 CN disclosed
CN-116715597-A Production process of levothyroxine sodium 湖北潜龙药业有限公司 2023-09-08 CN disclosed
CN-109761830-B Preparation method of levothyroxine sodium 珐玛赫(天津)科技有限公司 2021-12-17 CN disclosed
CN-109761830-B Preparation method of levothyroxine sodium 珐玛赫(天津)科技有限公司 2021-12-17 CN disclosed
EP-3024326-B1 NOVEL PROCESS FOR THE PREPARATION OF LEVOTHYROXINE SODIUM AZICO BIOPHORE INDIA PRIVATE LTD (IN) 2018-12-12 EP disclosed
US-9428444-B2 Process for the preparation of levothyroxine sodium AZICO BIOPHORE INDIA PRIVATE LIMITED (IN) 2016-08-30 US disclosed
US-20160168076-A1 NOVEL PROCESS FOR THE PREPARATION OF LEVOTHYROXINE SODIUM AZICO BIOPHORE INDIA PRIVATE LIMITED (IN) 2016-06-16 US disclosed
EP-3024326-A1 NOVEL PROCESS FOR THE PREPARATION OF LEVOTHYROXINE SODIUM Azico Biophore India Private Limited (IN) 2016-06-01 EP disclosed
WO-2015011573-A1 NOVEL PROCESS FOR THE PREPARATION OF LEVOTHYROXINE SODIUM AZICO PHARMACEUTICALS PRIVATE LIMITED (IN) 2015-01-29 WO disclosed
EP-0612308-B1 METHOD FOR PREPARING RADIO-IODINATED THYRONINE DERIVATIVES; NOVEL INTERMEDIATES HENNING BERLIN GMBH (DE) 1997-02-05 EP disclosed
EP-0612308-A1 METHOD FOR PREPARING RADIO-IODINATED THYRONINE DERIVATIVES; NOVEL INTERMEDIATES. HENNING BERLIN GMBH (DE) 1994-08-31 EP disclosed
WO-1993009076-A1 METHOD FOR PREPARING RADIO-IODINATED THYRONINE DERIVATIVES; NOVEL INTERMEDIATES HENNING BERLIN GMBH CHEMIE- UND PHARMAWERK (DE) 1993-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168076-A1 NOVEL PROCESS FOR THE PREPARATION OF LEVOTHYROXINE SODIUM TPO, TH, TYR PCNA 2907/4885TACR1 1336/4885ALDH1A1 771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.